Aerpio Therapeutics grabs $22 mln

Aerpio Therapeutics said Wednesday that it has raised $22 million in funding. OrbiMed led the round with participation from return backers Novartis Venture Funds, Satter Investment Management, Kearny Venture Partners, Venture Investors, Triathlon Medical Ventures and Athenian Venture Partners. In addition to the funding, OrbiMed’s Chau Q. Khuong has been added to Aerpio’s board of directors. Based in Cincinnati, Aerpio Therapeutics is a biopharmaceutical firm focused on therapies for vascular diseases.

VC-backed Akebia Therapeutics launches IPO

Akebia Therapeutics has launched its IPO of over 5.8 million shares at $17 per share. The stock began trading Thursday on the NASDAQ under the ticker symbol “AKBA.” Morgan Stanley, Credit Suisse and UBS Investment Bank are the lead underwriters. Based in Cincinnati, OH, Akebia Therapeutics is a biotech company focused on developing treatments for anemia and cancer. Its backers include Satter Investment Management, Novo A/S, Novartis Venture Funds, Kearny Venture Partners, Athenian Venture Partners and Triathlon Medical Ventures.

Aileron Therapeutics secures new financing

Aileron Therapeutics has secured $30 million in Series E equity financing from investors including Apple Tree Partners, Roche Venture Fund, Novartis Venture Funds, Lilly Ventures, SR One and Excel Venture Management. The clinical stage biopharmaceutical company is developing therapeutics based on its proprietary Stapled Peptide drug platform.

eFFECTOR Therapeutics Raises $45 Million Series A

Biopharmaceutical company eFFECTOR Therapeutics has completed a $45 million Series A financing. Investors include U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners and Mission Bay Capital.

Tokai Pharmaceuticals Inks $35.5m Series E

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, has raised $35.5 million in a Series E financing. The financing round included both current investors, Apple Tree Partners and Novartis Venture Funds, as well as undisclosed angel investors.

Thesan Pharmaceuticals Closes $16m Series A

Thesan Pharmaceuticals has closed a $16 million Series A financing, co-led by Novo Ventures and Novartis Venture Funds. The company focuses on the development of novel approaches for the treatment of dermatological disorders.

Celladon Wraps Up $43M Round

Celladon Corp., a developer of treatments for cardiovascular diseases, has closed on $43 million in new capital. Pfizer Venture Investments led the round, which included investment from new backers Lundbeckfond Ventures, Novartis Venture Funds, H&Q Healthcare/Life Sciences Investors, and GBS Venture Partners. All previous investors participated in this round, including Enterprise Partners Venture Capital, Johnson […]

Takeda Pharmaceutical Buys VC-Backed Intellikine

Takeda Pharmaceutical Company, a listed, Japanese pharmaceutical research company, is buying venture-backed Intellikine Inc. Takeda will pay $190 million in cash, and up to $120 million in additional milestone payments. Intellikine was backed by at least $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.

Intellikine Adds $4M in Milestone Payments

Biopharma company Intellikine Inc. has sealed $4 million in new milestone payments as it begins two Phase 1 clinical trials of its drugs. The company, based in La Jolla, Calif., is backed by $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.

Advanced Animal Diagnostics Inks $11M

Advanced Animal Diagnostics, a developer of technologies to diagnose farm animal diseases, has closed on $11 million in Series B financing. Intersouth Partners led the round, which included participation from Novartis Venture Funds and other, unnamed investors. The company will use the financing to continue development of its diagnostic tests. Advanced Animal’s first on-farm product will focus on improving milk production and quality by controlling mastitis, an infection of the milk-producing gland of cows.

PEHUB Community

Join the 12493 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget